The pilot study was designed to evaluate the early effect of intravenous (i.v.) zoledronic acid (ZA) on renal function.
Introduction
Osteoporosis represents a major health issue in relation to the high prevalence of fractures, particularly in the elderly population. Treatment of the disease is therefore needed in cases of high fracture risk and includes mostly antiresorptive drugs. Among them, bisphosphonates have now been used for many years to improve bone mineral density and reduce the risk of fractures in osteoporotic patients [1] [2] [3] . Safety data show that bisphosphonates can be associated with specific side effects according to the duration of treatment and means of administration [4, 5] . Upper gastrointestinal issues and an acute phase response are commonly seen in new oral and intravenous (i.v.) bisphosphonate users, respectively, while atypical fractures could be associated with long-term use [4] [5] [6] . Data on possible association between atrial fibrillation and bisphosphonate administration are instead conflicting [2, 7] .
Nephrotoxicity is a possible acute effect of i.v. bisphosphonates administration, particularly zoledronic acid (ZA) [8] . Overall, ZA is contraindicated in patients with a glomerular filtration rate (GFR) < 30-35 ml À1 min À1 1.73 m
À2
and the general recommendation is to administer the drug in no less than 15 min and eventually prolong the infusion time in patients with lower GFR to avoid any renal issues [8, 9] . The pivotal trial reported a significantly higher proportion of patients treated with ZA having acute and transient renal events (defined as increase in serum creatinine of >0.5 mg dl
À1
9 to 11 days after infusion) compared to controls, but no deterioration of the creatinine clearance during long-term monitoring [2] . Boonen et al. extended this analysis and reported that the pre-to post-infusion changes in serum creatinine concentration were particularly evident in patients with baseline estimated creatinine clearance between 30 and 34 ml min À1 [9] . The evaluation of renal function over the 3 years of the study showed no difference between ZA acid group and placebo [9] . Luedders et al. reported no renal toxicity in patients with metastatic tumours treated with i.v. ZA or ibandronate [10] . In particular α 1 -and β 2 -microglobulin, albumin, α 2 -macroglobulin, IgG and C-reactive protein were evaluated, with no evidence of differences between the two groups [10] . No study has so far evaluated the acute effects of i.v. ZA on the kidneys through the inclusion of a panel of specific and sensitive biomarkers of renal damage. In the last decade the evaluation of acute renal damage has been included in the definition of acute kidney injury (AKI) [11, 12] . AKI identifies the rapid onset of renal damage and involves those disorders of the kidney developing before the loss of excretory function as measured by standard laboratory tests [11, 12] . Accordingly, AKI could be caused by decreased renal or intra-renal perfusion, obstructive or toxic renal tubular disorders, tubular-interstitial inflammation and oedema, or decrease of glomerular filtration capacity [12] . Several biomarkers of AKI have been identified and associated with a good capability for early detection of kidney injury, good diagnostic performance and a better evaluation of prognosis in terms of need for renal replacement and/or survival [12] . Among AKI biomarkers, urinary neutrophil gelatinase-associated lipocalin (NGAL) demonstrated a good performance in predicting AKI in critically ill patients, after kidney transplantation and cardiac surgery [12, 13] . The molecule is derived predominantly from the epithelial cells of the distal nephron and accumulates in the proximal tubule 2-6 h after ischaemic and toxic acute tubular necrosis according to the severity and duration of renal damage, and high urine concentration persists up to 24 h [14] [15] [16] .
The kidney injury molecule-1 (KIM-1) is a transmembrane protein whose expression is highly increased in the proximal tubule in rats after ischaemic injury [17] . Clinical studies showed similar data in biopsies of patients with acute tubular necrosis and demonstrated that increased concentration of KIM-1 can also be detected in the urine with a high specificity for acute proximal tubular necrosis as soon as 24 h after the insult [18] . Additionally, KIM-1 is increased in patients with chronic kidney disease and active lupus nephritis [19] . The monocyte chemoattractant protein-1 (MCP-1) is a key regulator of the immune system as a potent chemotactic factor for monocytes/macrophages [20] . The molecule is produced predominantly by the monocyte/macrophage system, but also by fibroblasts, endothelial, epithelial, smooth muscle, mesangial, astrocytic, monocytic and microglial cells [20] . Mechanisms associated with migration and infiltration of monocytes are essential for immunological surveillance and response to inflammation in different tissues [20] . As such, genetic variants of MCP-1 and its receptor have been found to influence the serum concentration of the molecule and to be directly associated with the incidence and the pathogenesis of various diseases (cardiovascular disease, HIV infection, cancer) [20, 21] . The chemokine produced by renal cells has therefore been recognized as a highly specific mediator in acute ischaemic and toxic kidney injury, with elevated concentration detected in the urine in critically ill patients who developed AKI in the ICU on Day 2 [14] .
As for MCP-1, interleukin 18 (IL-18) [22] is produced by a number of cells, including macrophages, dendritic and Kupffer cells, keratinocytes, osteoblasts, adrenal cortex, intestinal epithelial, microglial cells and synovial fibroblasts [23] . It is constitutively expressed in the kidneys in the intercalated cells of the distal convoluted tubule, the connecting tubule, and the collecting duct and was found to be a mediator of ischemic AKI in mice [24] . Studies in humans showed that urinary IL-18 increases 4-24 h after cardiopulmonary bypass and in patients with acute respiratory distress syndrome [24] . Drug-induced AKI is not an uncommon condition, particularly among critically ill patients and the prompt identification of nephrotoxic agents is needed to avoid any further deterioration of renal function [12] . Antibiotics, antimycotics, antivirals, NSAIDs, immunosuppressant and antineoplastic drugs, radiocontrast agents, angiotensin converting-enzyme inhibitors and angiotensin-receptor blockers are usually listed among drugs contributing to AKI; few data are available on the use of the novel biomarkers in detecting drug-induced AKI [12, 25, 26] . Finally, no study so far has focused on the evaluation of AKI biomarkers in bisphosphonate users.
In this study, we sought to evaluate the early effect of i.v. ZA on renal function and define the potential role of AKI biomarkers in unveiling subtle damage and the possible associated mechanisms.
Methods
A total of 23 patients (17 women and 6 men, mean age 73 ± 7 SD years) consecutively referred to our Mineral Metabolism Unit from 2014 to 2015 were assessed. The patients had densitometric osteoporosis and/or fragility fractures, and were candidates for treatment with ZA.
Patients were excluded if they had estimated (e) GFR < 30 ml min À1 , nephrotic syndrome, chronic inflammatory diseases (such as connective tissue diseases, rheumatoid arthritis, systemic lupus erythematosus, inflammatory bowel diseases), recent (<3 months) systemic or urinary tract infections and/or treatment with antibiotics and/or antimycotics, use of ACE-inhibitor drugs, sartans, multiple myeloma, cancer, diabetes, recent (< 3 months) radiological exam with iodinated contrast media, or heart failure. Any treatment with non-steroidal anti-inflammatory drugs was withdrawn at least 48 h prior to the baseline visit. All subjects were placed on a standardized diet with 1000-1500 mg of elemental calcium per day, as well as vitamin D supplementation at the dose of 800 IU daily, starting 2 months before the beginning of the study. Zoledronic acid 5 mg/100 ml was administered for the first time to fasting patients as a 30-min i.v. infusion at 09:00. The 30-min time of infusion was chosen to avoid any possible effect of the drug on the kidneys related to a faster administration [8, 9] . The occurrence of a transient acute phase reaction, defined by the presence of fever, myalgias and arthralgias occurring soon after the infusion and lasting 24-72 h after the dose, was recorded for Day 1 visit and by phone call monitoring afterwards.
Fasting blood samples were drawn in all patients before the infusion and at 24 h (the day after the infusion at 09:00) and at Day 30, and serum calcium (sCa), phosphorus (sP), creatinine (sCr), parathyroid hormone (PTH) [27] , Cterminal fibroblast growth factor-23 (FGF23) [22, 28] , serum Klotho (sKlotho) were measured. A 24-hour urine collection was also obtained on all patients at baseline and 30 days after the infusion, and a morning fasting 3-h urine sample was collected at 24 h to measure calcium and phosphate excretion; calcium tubular reabsorption was expressed as excretion per unit of creatinine clearance [milligrams per deciliter of GFR (CaEx)]. The ratio of the maximum rate of renal tubular reabsorption of phosphate to GFR [renal threshold phosphate concentration/GFR TmPO 4 /GFR)] was determined using the nomogram of Walton and Bijvoet [29, 30] . Creatinine clearance (CrCl) was obtained at baseline and Day 30 using the following formula:
The following AKI biomarkers were assessed at baseline and at 24 h and Day 30 after administration of the drug: uNGAL, uKIM-1 and uMCP-1; plasma MCP-1 (pMCP-1) and serum interleukin 18 (sIL-18). Those biomarkers were chosen as their early elevation has been detected in animal and clinical studies in association with intrarenal injury at different levels of the nephrons, and driven by several (ischaemic, toxic, inflammatory) insults [12, 14, 16, 18, 25] . Given the absence of any data on the possible mechanism of ZA action on the kidneys, the evaluation of a panel of specific markers of AKI whose mechanism of action exerts at different levels allows us to better define the possible renal effect of the drug and to eventually identify the associated mechanisms. The ratio between urinary AKI biomarkers and uCr was evaluated, as follows: uNGAL/uCr, uKIM-1/uCr, uMCP-1/uCr. The ratio was evaluated in order to adjust urinary excretion of AKI biomarkers for patients' renal function, being the baseline CrCl variable among subjects and ranging from normal renal function to mild-to-moderate renal impairment.
Serum and urinary concentration of Ca, P and Cr was measured by a Cobas 6000 analyser (Roche Diagnostics, Switzerland). Serum immunoreactive PTH 1-84 concentration was measured by LIAISON (Diasorin, Stillwater, MN, USA); the intra-and inter-assay coefficients of variation (CVs) were 8.1 and 10.2%, respectively. Plasma FGF23 concentration was measured by the secondgeneration ELISA (Immunotopics, Inc., San Clemente, CA, USA) that detects both the intact FGF23 and the C-terminal fragments. Intra-and inter-assay CVs were 8.0 and 7.0 at plasma concentrations of 25 and 300 RU ml À1 , respectively.
Serum Klotho was measured by ELISA (ImmunoBiological Laboratories Co., Ltd., Japan). Intra-and inter-assay CVs were 3.1% and 6.93%, respectively. The other AKI biomarkers were measured by ELISA (R&D Systems, Inc., Minneapolis, MN, USA). Intra-and inter-assay CVs were 3.7% and 6.53% for uNGAL, 4.2% and 6.73% for uKIM-1, 5% and 5.07% for urinary and plasma MCP-1, 7.26% and 7.53% for sIL-18, respectively. Blood samples were stored at À70°C [31] [32] [33] and the assays were performed in one batch at the end of the study.
Written informed consent was obtained from all participants after full explanation of the study details.
The protocol was approved by the 'Policlinico Umberto I di Roma' Ethics Committee.
Statistical analysis
Results are presented as mean values ± SD. Linear mixed models for repeated measures were applied to assess the parameter change at different time points, with time, group and time-group interaction term as the fixed effect, adjusted for sex and age. P-values < 0.05 were considered significant and the R package (version 3.02) was used for statistical calculations.
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www. guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY [34] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2015/16 [22, 27, 28] .
Results Table 1 shows demographic characteristics of the study population, and serum and urinary concentration of the parameters of mineral metabolism and the AKI biomarkers at any time point.
As shown, mean serum PTH was above the normal range as soon as 24 h after the infusion and up to 30 days. Among AKI biomarkers, only pMCP-1 was above the normal range at 24 h (Table 1) .
There was a significant decrease in sCa at 24 h (À4.1 ± 2.8%; P < 0.01) and Day 30 (À3.9 ± 4%; P < 0.01) (Figure 1) . No case of hypocalcaemia was reported and patients had no symptoms possibly related to hypocalcaemia. There was no significant change in serum P and Cr concentration (data not shown). Data showed an increase in serum PTH of 29.8 ± 37.7% at 24 h which was marginally significant (P = 0.09) and a significant increase of 79.8 ± 95.8% at Day 30 (P < 0.001) (Figure 1 ), compared to baseline. There was a 28 ± 59% and 26 ± 43% decrease in CaEx at 24 h (P < 0.05) and Table 1 Demographic characteristics and laboratory findings (mean ± SD) in the 23 subjects with osteoporosis. Parameters whose serum levels were above the normal range are bold Day 30 (P < 0.01) (Figure 1 ) compared to baseline. TmPO 4 / GFR decreased significantly at 24 h and Day 30 (À8.6 ± 15.9%, P < 0.05 and À11.3 ± 13.5%, P < 0.01) (Figure 1 ).
Mean CrCl values did not significantly change at Day 30 in respect to baseline values. We observed no difference in plasma C-terminal FGF23 and sKlotho concentration at any time point compared to baseline.
No significant baseline changes in the concentration of urinary AKI biomarkers were detected after adjusting for uCr (data not shown). Mean sIL-18 and pMCP-1 significantly increased at Day 1 (44 ± 88%; P < 0.01 and 198 ± 237%; P < 0.001) and returned to baseline at Day 30 ( Figure 1) .
Ten of the 23 patients (43%) experienced a transient acute phase reaction. At Day 1 we observed a trend towards a significant difference in terms of increase in pMCP-1 concentration between patients experiencing the acute phase reaction (+296 ± 317.3%) and those not having the reaction (+150 ± 167.6%, P = 0.05).
Discussion
Our study investigated for the first time the very early effect of ZA on the kidneys and excluded any detrimental action of the drug on renal function, evaluated by a panel of specific biomarkers of acute kidney injury. We also looked at the metabolic profile of patients after ZA administration and observed an increase in serum PTH concentration secondary to a slight decrease in serum calcium. Metabolic mechanisms stimulated by i.v. ZA injection seem therefore not to be associated with any acute renal injury in the very short term, but rather with perturbation of the calcium-phosphorus metabolism.
Many data on AKI have been published in the last decade showing that AKI biomarkers are rapidly produced and increased concentration can be detected 2-24 h after the acute injury [12] . Hence, they are useful in detecting kidney damage sooner than creatinine and in several clinical settings [11-14, 17, 25, 35-37] . Hence, our cohort of osteoporosis patients with normal renal function or mild renal impairment was chosen in order to evaluate the sensitivity of these biomarkers in detecting early kidney injury specifically associated with ZA infusion and not influenced by possible underlying renal diseases. For the same reason, patients with diseases (e.g. diabetes) and/or taking medications possibly affecting the kidneys were excluded from the study.
Our data showed that urinary NGAL, KIM-1 and MCP-1 did not change significantly during the period when the urinary concentration was adjusted for urinary creatinine excretion to take into account patients' renal function. Given the diagnostic values of the three urinary biomarkers in the early detection of renal damage as soon as 1 day after the insult [12] , our results demonstrated the absence of any acute toxic effects of i.v. ZA on the kidneys. This point is further supported by the fact that mean urinary concentration of the aforementioned markers remained within the normal range during the observation. Also, the prognostic value of NGAL and KIM-1 [12] is consistent with the absence of any specific kidney insult of the drug in patients with normal or mild to moderate reduction of renal function. Consistently, there was no significant change in serum creatinine at any time point, nor in ClCr at Day 30, thus confirming that the administration of ZA does not cause any acute kidney injury, as defined on the basis of the KDIGO criteria [38] and also on the basis of the new, more specific, markers of renal injury assessment.
Results showed that plasma MCP-1 and serum IL-18 were above the normal range as soon as 24 h compared to baseline. Nevertheless, the lack of changes in the urinary biomarkers seems to exclude the possibility to consider this data as diagnostic for AKI. Plasma concentration of these proteins could indeed rise in many inflammatory conditions and their increase after ZA infusion could be expression of the perturbation of immunological mechanisms stimulated by the drug and particularly those involving the Figure 1 Mean values of, serum calcium (sCa), PTH, calcium excretion (CaEx), TmPO 4 /GFR (panel A) and plasma MCP-1 and serum IL-18 (panel B) percent basal difference at any time point. * P < 0.001; * * P < 0.01; * * * P < 0.05 monocyte/macrophage system [20, 39] . The higher increase in plasma MCP-1 in patients experiencing the acute phase reaction could also raise the hypothesis that the cytokine is associated with this typical transient side effect of i.v. bisphosphonates. Finally, previous data in patients with lupus nephritis demonstrated that urinary and not serum MCP-1 is useful in the assessment of renal complication as it correlates with clinical and laboratory parameters of renal disease [40] .
Our study reported for the first time the early effect of an i.v. bisphosphonate on the PTH-FGF23 axis. Consistent with previous data [2, 41, 42] , there is an early, as soon as 1 day, increase in serum PTH in response to the decrease in serum calcium, which drives the reduction in calcium excretion and in the renal tubular reabsorption of phosphate. Interestingly, serum PTH continues to increase up to 30 days after the infusion of ZA. Gonnelli et al. reported significant increases in serum PTH and no changes in serum calcium and creatinine 1 year after ZA administration in 29 postmenopausal women with osteoporosis [41] . The overall results of the present and previous studies seem therefore to show that there is a rapid response of the parathyroid glands to ZA administration in terms of secretion of PTH, whose serum concentration is elevated up to 1 year after the injection and even in the setting of no apparent hypocalcaemia and no perturbation of renal function [41] .
Among other causes of secondary hyperparathyroidism, we can also exclude any hypovitaminosis D, as patients were receiving supplementation during the entire course of the study. It is also interesting to note that there was no change in P and FGF23 concentration, as well as its co-receptor, Klotho; this point further supports the finding of no acute kidney injury associated with ZA administration. Indeed, FGF23 concentration is typically elevated in patients with AKI, with a strong correlation with worse outcomes [43] . Furthermore, the increase in FGF23 during acute kidney dysfunction is independent of the vitamin D-PTH pathway and this is consistent with the presence of elevated PTH in our study, not associated with any changes in markers of renal function [43] . Klotho is a transmembrane protein with multiple biological functions, whose expression in the distal nephron and proximal tubule lumen is severely downregulated during AKI [43] . Klotho deficiency in the kidneys, urine and blood is therefore a marker of kidney disease and displays earlier than NGAL increase during AKI [44, 45] . The only study so far evaluating the effect of intravenous bisphosphonates on the FGF23 axis is the one by Gonnelli et al. showing that FGF23 serum concentration decreases significantly without changes in serum P and in the renal function in patients receiving ZA [41] . Nevertheless, the authors reported data at 1 year. We can therefore speculate that mechanisms other than hypophosphataemia and impaired renal function, possibly associated with a direct action of the drug on bone cells producing FGF23 and acting in the long term (more than 30 days), have to be taken into account.
Clinical implications of our findings include confirmation of the safety of ZA, particularly when administered as a 30-min infusion, in patients with normal GFR, and mild to moderate renal impairment [8, 46] . Indeed, AKI typically has a rapid onset and can be disregarded when only the routine biochemical evaluation is performed, while the assessment of a combination of different specific biomarkers of acute damage, other than the use of single ones, can improve our ability to predict AKI and its outcomes in a context-specific manner, including drug-induced toxicity [12] . Also, as AKI biomarkers provide useful and specific information on the pathogenesis of kidney disease, we can exclude any possible direct toxic effect of ZA on the proximal and distal tubules [14] . The confirmation that there is an acute onset of secondary hyperparathyroidism in patients receiving i.v. ZA with consequent changes in the mineral metabolism pattern needs to be further assessed over the long term.
Limitations of our study pertain to the small sample size and the absence of a control group that would have given the possibility of better addressing the primary endpoint. Also, the presence of urinary protein data would have improved the strength of the results. Finally, our data are limited at 30 days and no evaluation of metabolic changes has been performed after this time point. Nevertheless, this is to our knowledge the first study reporting a complete evaluation of mechanisms linking ZA to kidney function and could represent a pilot study in the field.
In conclusion, our pilot study suggests that, using a highly sensitive and specific panel of AKI biomarkers, there is no direct acute effect of ZA on kidney function in patients with normal GFR or mild to moderate renal impairment. As conditions possibly influencing renal function were excluded from the study, we cannot exclude the possibility that results may differ in more vulnerable populations with more risk factors for AKI.
The increase in plasma MCP-1 and serum IL-18 concentration could be associated with the stimulation of immunity mechanisms occurring soon after the administration of the drug. Finally, secondary hyperparathyroidism develops shortly after the infusion of ZA and is maintained even after 1 month. This data requires further studies in order to assess the long-term effect of high serum PTH in osteoporosis patients treated with ZA.
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